Sanofi Seeks FDA Withdrawal of Diabetes Drug from Fast-Track Review Amid Political Concerns
In a notable move, Sanofi has requested the FDA to withdraw its type 1 diabetes drug from the expedited review process, citing political interference as a key factor.